Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study von Hong, Xiaonan, Song, Yuqin, Shi, Yuankai, Zhang, Qingyuan, Guo, Wei, Wu, Gang, Li, Junmin, Feng, Jifeng, Kinkolykh, Anastasiia, Knapp, Andrea, Lin, Tongyu

Volltext

First-line immunochemotherapy for follicular lymphoma in the GALLIUM study: Prognostic value of PET-CT status after long-term follow-up von Nielsen, Tina, Barrington, Sally, Meignan, Michel, Sahin, Deniz, Knapp, Andrea, Kinkolykh, Anastasiia, Herold, Michael, Hiddemann, Wolfgang, Marcus, Robert, Trotman, Judith

Volltext

MRI and Clinical Outcomes of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Relapsing Multiple Sclerosis Over 2.5 Years of the Open-Label Extension to a Phase 2 Trial von Vermersch, Patrick, Arnold, Douglas L, Wolinsky, Jerry, Havrdova, Eva Kubala, Kinkolykh, Anastasiia, Hyvert, Yann, Tomic, Davorka, Montalban, Xavier

Volltext

Effect of Evobrutinib, a Bruton's Tyrosine Kinase Inhibitor, on Patient-Reported Vitality and Mental Health in Patients with Relapsing Multiple Sclerosis in a Phase 2 Trial von Vermersch, Patrick, Giovannoni, Gavin, Wolinsky, Jerry, Arnold, Douglas L., Kamudoni, Paul, Meier, Daniela Piani, Thangavelu, Karthinathan, Kinkolykh, Anastasiia, Hyvert, Yann, Tomic, Davorka, Montalban, Xavier

Volltext

Résultats cliniques et d’imagerie par résonance magnétique de l’évobrutinib (EVO), un inhibiteur de la tyrosine kinase de Bruton (BTKi), dans le traitement de la sclérose en plaque... von Vermersch, Patrick, Arnold, Douglas, Wolinsky, Jerry S., Hardova, Eva Kubala, Kinkolykh, Anastasiia, Tomic, Davorka, Montalban, Xavier

Volltext